Endotype–phenotyping may predict a treatment response in progressive fibrosing interstitial lung disease

BACKGROUND: Some interstitial lung disease (ILD) patients develop a progressive fibrosing-ILD phenotype (PF-ILD), with similar persistent lung function decline suggesting common molecular pathways involved. Nintedanib, a tyrosine kinase inhibitor targeting the PDGF, FGF, VEGF and M-CSF pathways, has...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann-Vold, Anna-Maria, Weigt, S. Samuel, Saggar, Rajan, Palchevskiy, Vyacheslav, Volkmann, Elizabeth R., Liang, Lloyd L., Ross, David, Ardehali, Abbas, Lynch, Joseph P., Belperio, John A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921223/
https://www.ncbi.nlm.nih.gov/pubmed/31732480
http://dx.doi.org/10.1016/j.ebiom.2019.10.050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6921223/
https://www.ncbi.nlm.nih.gov/pubmed/31732480
http://dx.doi.org/10.1016/j.ebiom.2019.10.050

Ejemplares similares